System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Igor Puzanov is an expert in Oncology at Roswell Park Cancer Institute (United States). As of June 2026, ScienceLeadR ranks Igor Puzanov in the top 1% of experts worldwide for Melanoma and Skin Neoplasms. Igor Puzanov has authored 444 publications, the most recent in 2026, and is an investigator in 34 clinical trials, 2 of them ongoing. SLR score: 1,808 (community average: 125). How the SLR is computed.

LeadR Profile

Igor Puzanov Roswell Park Cancer Institute United States
1 808 ScienceLeadR Reputation 1808

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pharmacy - Biochemistry - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2016 - 2026
Source: PubMed

Roswell Park Cancer Institute

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 444

Citations

Citations: 57 473 1st author: 29 Last author: 54 Unique author: 1

Main journals

J Clin Oncol 113
J Immunother Cancer 31
J Transl Med 30
Ann Oncol 28
Cancer Res 22

Best Journals

J Clin Oncol 22
Ann Oncol 10
N Engl J Med 10

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.
PMID 42297031 — melanoma, neoplasms		J Natl Compr Canc Netw20262
Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer.
PMID 42067541 — cells, genes, bcl-2, neoplasms, prostate, prostatic neoplasms, signal transduction, castration, therapeutics, heterografts		Signal Transduct Target Ther Top journal20260
IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.
PMID 42025759 — cells, vaccines, progression-free survival, melanoma, neoplasms, drug-related side effects and adverse reactions, cancer vaccines		Ann Oncol Top journal20260
Infusion-Related Reactions from Immune Checkpoint Inhibitors in Solid Tumors: A Proportional and Network Meta-Analysis.
PMID 41996022 — incidence, neoplasms, immune checkpoint inhibitors, network meta-analysis, therapeutics		Target Oncol20260
Translating ctDNA into cutaneous melanoma care: An international expert survey.
PMID 41932032 — melanoma, translating, neoplasms		Eur J Cancer20260

Clinical Studies 34

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 5

By phase:

Phase 2 13
Phase 1 8
Phase 1/Phase 2 6
Phase 3 5
N/A 1
Phase 2/Phase 3 1

By status:

Completed 27
Active not recruiting 3
Terminated 3
Recruiting 1

By type:

Interventional 33
Observational 1

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 1
multicentric5to9 2
multicentricup10 24

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
IDE196 (Darovasertib) in Combination With Crizotinib as First line Therapy in Metastatic Uveal Melanoma
NCT05987332 — protein kinase c, protein kinases, ophthalmology, melanoma, dacarbazine, multiple chronic conditions, maintenance, hla-a2 antigen, nivolumab, therapeutics, ipilimumab, crizotinib, uveal melanoma		Phase 2/Phase 3Active not recruiting2023
Phase 1a and Phase 2 Study for Safety Preliminary Efficacy PK and PD of ST 067
NCT04787042 — cells, triple negative breast neoplasms, lung, epitopes, safety, breast neoplasms, carcinoma, squamous cell, melanoma, neoplasms, carcinoma, non-small-cell lung, carcinoma, renal cell, immunoglobulins, solutions, squamous cell carcinoma of head and neck, lung neoplasms, small cell lung carcinoma, breast, antibodies, monoclonal, therapeutics, interleukin-18, b-lymphocytes, msi-h, carcinoma		Phase 1/Phase 2Recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS